Copyright
©The Author(s) 2015.
World J Diabetes. Jul 25, 2015; 6(8): 990-998
Published online Jul 25, 2015. doi: 10.4239/wjd.v6.i8.990
Published online Jul 25, 2015. doi: 10.4239/wjd.v6.i8.990
RCT | Study details | Outcome | Diabetes remission |
Dixon et al[8] | Un-blinded RCT. N = 60 Obese patients with recent onset T2DM Conventional therapy vs LAGB Follow-up: 2 yr | Weight loss –1.7% ± 5.2% in conventional group and –20.7% ± 8.6% in the surgical group | 73% in surgical group 13% in conventional group (Remission of T2DM defined as FBS < 7.0 mmol/L and HbA1c < 6.2%) |
Mingrone et al[7] | Single centre non-blinded RCT. N = 60. Severely obese patients. T2DM of at least 5 yr duration and HbA1c > 7.0%. Conventional medical therapy vs RYGB or BPD Follow-up: 2 yr | Weight loss −4.7% ± 6.3% with medical therapy, −33.3% ± 7.8% with RYGB and −33.8% ± 10.1% with BPD | 75% in RYGB group; 95% in BPD group. None in the conventional group (Remission defined as FBS < 5.6 mmol/L and HbA1c < 6.5%) |
Schauer et al[9] | Single centre non-blinded RCT in obese uncontrolled T2DM. N = 150 Intensive medical therapy vs RYGB or SG Follow-up: 12 mo | Weight loss –5.4 ± 8.0 kg in medical therapy group, -29.4 ± 9.0 kg in RYGB group and –25.1 ± 8.5 kg in SG group | 12% medical therapy group 42% in RYGB group 37% SG group (Remission/primary outcome defined as HbA1c of 6% or less) |
Ikramuddin et al[10] | Un-blinded RCT in obese T2DM with HbA1c over 8% with average duration of 9 yr. N = 120 Intensive medical therapy vs RYGB Follow-up: 12 mo | Difference in weight loss between surgical and medical group –17.1 ± 5.6 kg. % weight change in medical vs Surgical group –7.9 ± 2 vs–26 ± 2 | 75% RYGB group 32% in medical group (Remission defined as HbA1c < 7%) |
Liang et al[11] | RCT in obese T2DM. N = 108. RYGB compared with standard care with or without Exenatide therapy Follow-up: 12 mo | Reduction in BMI (kg/m2) in standard vs Exenatide vs RYGB: –0.56 ± 1.66 vs–3.44 ± 1.21 vs–5.97 ± 0.91 | 90% in RYGB group None in patients receiving standard care with or without Exenatide (Remission defined as HbA1c < 6.5%) |
Bariatric | Body mass index (kg/m2) | HbA1c (%) | ||||
procedure | Pre-surgery | Post-surgery | Mean reduction (95%CI) | Pre-surgery | Post-surgery | Mean reduction (95%CI) |
AGB | 37 | 29.5 | 7.5 (5.9-9.1) | 7.8 | 6 | 1.8 (1.3-2.3) |
SG | 41.3 | 28.3 | 13.0 (10.1-15.9) | 7.9 | 6 | 1.9 (1.0-2.8) |
RYGB | 34.6 | 25.8 | 8.8 (5.2-12.4) | 8.2 | 6.1 | 2.1 (1.3-2.9) |
BPD | 50.5 | 34.6 | 15.9 (11.8-20.0) | 8 | 5.2 | 2.8 (2.1-3.5) |
- Citation: Pappachan JM, Viswanath AK. Metabolic surgery: A paradigm shift in type 2 diabetes management. World J Diabetes 2015; 6(8): 990-998
- URL: https://www.wjgnet.com/1948-9358/full/v6/i8/990.htm
- DOI: https://dx.doi.org/10.4239/wjd.v6.i8.990